e10vkza
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K/A
Amendment No. 1
(Mark One)
|
|
|
þ |
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 |
For the fiscal year ended December 31, 2008
OR
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 0-17758
EMISPHERE TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
13-3306985 |
(State or other jurisdiction of
|
|
(I.R.S. Employer |
incorporation or organization)
|
|
Identification Number) |
|
|
|
240 Cedar Knolls Road, Suite 200 |
|
|
Cedar Knolls, NJ
|
|
07927 |
(Address of principal executive offices)
|
|
(Zip Code) |
(973) 532-8000
(Registrants telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock $.01 par value
Preferred Stock Purchase Rights
Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in
Rule 405 of the Securities Act. Yes o No þ
Indicate by check mark if the Registrant is not required to file reports pursuant to
Section 13 or 15(d) of the Act. Yes o No þ
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that Registrant was required to file such reports) and (2) has been subject
to such filing requirements for at least the past 90 days. Yes þ No o
Indicate by check mark whether the
registrant has submitted electronically and posted on its corporate
Web site, if any, every Interactive Data file required to be
submitted and posted pursuant to Rule 405 of Regulation S-T during the
preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files).
Yes o No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of
Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to
the best of registrants knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-K or any amendment to this Form 10-K. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large
accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer o
|
|
Accelerated filer þ
|
|
Non-accelerated filer o
|
|
Smaller reporting company o |
|
|
|
|
(Do not check if a smaller reporting company) |
|
|
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of
the Act). Yes o No þ
As of June 30, 2008 (the last business day of the registrants most recently completed second
quarter), the aggregate market value of the common stock held by non-affiliates of the Registrant
(i.e. excluding shares held by executive officers, directors, and control persons) was $68,662,707
computed at the closing price on that date.
The number of shares of the Registrants common stock, $.01 par value, outstanding as of
March 11, 2009 was 30,341,078.
TABLE OF CONTENTS
EXPLANATORY NOTE
This Amendment No. 1 on Form 10-K/A (this Amendment) amends the Registrants Annual Report
on Form 10-K for the fiscal year ended December 31, 2008, originally filed on March 16, 2009 (the
Original Filing). Due to the Registrants receipt on April 30, 2009 of the resignation of Steven
K. Carter, M.D. as a Director of the Registrants Board of Directors, the Registrant is amending
Part III to include the information required by Items 10, 11, 12, 13 and 14 of Part III within the
period required by General Instruction G(3) to Form 10-K. The reference on the cover of the Report
to the incorporation by reference of the Registrants definitive proxy statement into Part III of
the Report is hereby amended to delete that reference. In addition, in connection with the filing
of this Amendment and pursuant to the rules of the Securities and Exchange Commission, the
Registrant is including with this Amendment certain currently dated certifications. Except as
otherwise stated herein, no other information contained in the Original Filing is amended hereby.
In order to preserve the nature and character of the disclosures set forth in the Original
Filing, except for the information in Part III and as otherwise stated herein, this report speaks
as of the date of the filing of the Original Filing, March 16, 2009, and we have not updated the
disclosures in this report or the Original Filing to speak as of a later date.
Unless
the context requires otherwise, references in this Amendment to
Emisphere, the Company, we, us, and
our refer to Emisphere Technologies, Inc.
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Director
and Executive Officer Information
Our current directors and executive officers and their ages as of April 1, 2009 are as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year |
|
|
|
|
|
|
|
|
Joined |
|
|
Name |
|
Age |
|
Emisphere |
|
Position with the Company |
Michael V. Novinski
|
|
|
52 |
|
|
|
2007 |
|
|
President and Chief Executive Officer,
Class III Director |
Michael R. Garone
|
|
|
50 |
|
|
|
2007 |
|
|
Vice President, Chief Financial Officer
and Corporate Secretary |
M. Gary I. Riley, DVM, PhD
|
|
|
66 |
|
|
|
2007 |
|
|
Vice President of Non-Clinical
Development and Applied Biology |
Stephen K. Carter, M.D. (1)
|
|
|
71 |
|
|
|
2003 |
|
|
Class I Director |
John D. Harkey, Jr.
|
|
|
48 |
|
|
|
2006 |
|
|
Class I Director |
Kenneth I. Moch
|
|
|
54 |
|
|
|
2008 |
|
|
Class II Director |
Mark H. Rachesky, M.D.
|
|
|
50 |
|
|
|
2005 |
|
|
Class III Director |
Michael Weiser, M.D.
|
|
|
46 |
|
|
|
2005 |
|
|
Class III Director |
|
|
|
(1) |
|
Dr. Carter resigned from the Board of Directors effective April 30, 2009. |
Michael V. Novinski joined Emisphere in 2007 as President and Chief Executive Officer.
Mr. Novinski has been a Director of the Company since 2008. Immediately before joining the Company,
Mr. Novinski was President and a member of the Board of Directors of Organon USA Inc., a business
unit of Organon BioSciences Inc. Mr. Novinski served as Organons Director of Marketing beginning
in 1992 and held several senior executive positions within Organon BioSciences prior to becoming
President of Organon USA in 2003. Mr. Novinski earned a Bachelors degree with a major in Biology
from Washington and Jefferson College in Washington, PA. He also studied under fellowship at the
University of Pittsburgh Medical School, Department of Microbiology.
Michael R. Garone joined Emisphere in 2007 as Vice President and Chief Financial Officer.
Mr. Garone has also served as the Companys Corporate Secretary since October 2008. Mr. Garone
previously served as Interim Chief Executive Officer and Chief Financial Officer of Astralis, Ltd.
(OTC BB: ASTR.OB) Mr. Garone spent 20 years at AT&T (NYSE: T), where he held several positions,
including Chief Financial Officer of AT&T Alascom. Mr. Garone received a MBA from Columbia
University and a BA in Mathematics from Colgate University, Hamilton, NY.
M. Gary I. Riley DVM, PhD joined Emisphere in November 2007 as Vice-President of Nonclinical
Development and Applied Biology. He was previously Vice President of Toxicology and Applied Biology
at Alkermes, Inc., Cambridge, MA, where he spent 14 years working in the field of specialized drug
delivery systems. He holds board certifications in veterinary pathology and toxicology. He was
previously employed as Director of
Pathobiology at Lederle Laboratories and earlier in his career held positions as a veterinary
pathologist in academia and industry.
Stephen K. Carter, M.D. has been a Director of the Company since 2003. He resigned from the
Board of Directors effective April 30, 2009. From 1996-2000, Dr. Carter was the Senior Vice
President of Clinical and Regulatory Affairs at Sugen, Inc. From 1995-1996, Dr. Carter served as a
Senior Vice President of Research and Development at Boehringer Ingelheim Pharmaceuticals, Inc.;
from 1990-1995, Dr. Carter served as Senior Vice President of Worldwide Clinical Research and
Development at Bristol-Myers Squibb Co. (NYSE: BMS). Dr. Carter currently serves on the Board of
Directors of Cytogen Corporation (NASDAQ: CYTO), Alfacell Corporation (NASDAQ: ACEL), Tapestry
Pharmaceuticals, Inc. (NASDAQ: TPPH), Callisto Pharmaceuticals, Inc. (AMEX: KAL), Vion
Pharmaceuticals, Inc. (NASDAQ: VION) and Celator.
John D. Harkey, Jr. has been a Director of the Company since 2006. Mr. Harkey is Chairman and
Chief Executive Officer of Consolidated Restaurant Companies, Inc., which owns, operates and
franchises full-service restaurants in the U.S., the Middle East and the United Kingdom. Mr. Harkey
also serves on the Board of Directors of Leap Wireless International, Inc. (NASDAQ:LEAP), Energy
Transfer companies (NYSE:ETE and ETP), Loral Space & Communications, Inc. (NASDAQ:LORL) and the
Baylor Health Care System Foundation. Mr. Harkey also serves on the Executive Board of Circle Ten
Council of the Boy Scouts of America and is a member of the Young Presidents Organization.
Mr. Harkey obtained a B.B.A. from the Business Honors Program at the University of Texas at Austin.
He earned an M.B.A from Stanford University School of Business and a J.D. from the University of
Texas School of Law.
Kenneth I. Moch has served as a Director of the Company since December 2008. Mr. Moch is the
President & CEO of BioMedical Enterprises, Inc., a medical device company which markets orthopaedic
memory metal implants. He is also is the Founder and President of Euclidean Life Science Advisors,
which provides strategic advisory services to life sciences companies. He is a former Managing
Director, Healthcare Investment Banking, of ThinkEquity Partners, an investment bank focusing on
high-growth companies, and former Chairman, President and Chief Executive Officer of Alteon, a
biotech company specializing in small molecule therapeutics for cardiovascular aging and diabetic
complications. He previously served as President and Chief Executive Officer of Biocyte
Corporation, the cellular therapy company that pioneered the collection and commercial application
of cord blood stem cells in transplantation and cellular therapy. Mr. Moch also serves on the
boards of M2Gen, a joint venture between Merck & Company and the Moffitt Cancer Center, and Virgin
Health Bank QSTP. Mr. Moch holds a degree in biochemistry from Princeton University and received
his MBA from the Stanford Graduate School of Business.
Mark H. Rachesky, M.D. has been a Director of the Company since 2005. Dr. Rachesky is the
co-founder and President of MHR Fund Management LLC and affiliates, investment managers of various
private investment funds that invest in inefficient market sectors, including special situation
equities and distressed investments. From 1990 through June 1996, Dr. Rachesky was employed by Carl
C. Icahn, initially as a senior investment officer and for the last three years as sole Managing
Director of Icahn Holding Corporation, and acting chief investment advisor. Dr. Rachesky is
currently the Non-Executive Chairman of the Board of Loral Space & Communications, Inc. (NASDAQ:
LORL), Telesat Canada and Leap Wireless International, Inc. (NASDAQ: LEAP) and is a member of the
Board of Directors of Nations Health, Inc. (NASDAQ: NHRX). Dr. Rachesky is a graduate of Stanford
University School of Medicine and Stanford University School of Business. Dr. Rachesky graduated
from the University of Pennsylvania with a major in Molecular Aspects of Cancer.
Michael Weiser, M.D., Ph.D has been a Director of the Company since 2005. Dr. Weiser is the
founder and co-chairman at Actin Biomed, a healthcare investment firm. Before joining Actin,
Dr. Weiser was the Director of Research of Paramount BioCapital, Inc. Dr. Weiser completed his
Ph.D. in Molecular Neurobiology at Cornell University Medical College and received his M.D. from
New York University School of Medicine, where he also completed a Postdoctoral Fellowship in the
Department of Physiology and Neuroscience. Dr. Weiser serves on the boards of Manhattan
Pharmaceuticals, Inc. (OTCBB: MHA), Hana Biosciences, Inc. (AMEX: HNAB), Chelsea Therapeutics
International Ltd. (NASDAQ: CHTP), Ziopharm Oncology, Inc. (NASDAQ: ZIOP), VioQuest
Pharmaceuticals, Inc. (OTCBB: VQPH) and several privately-held biotechnology companies.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act of 1934 (the Exchange Act), and the rules of
the Securities and Exchange Commission (the SEC) require our directors, Executive Officers and
persons who own more than 10% of Common Stock to file reports of their ownership and changes in
ownership of Common Stock with the SEC. Our employees sometimes prepare these reports on the basis
of information obtained from each director and Executive Officer. Based on written representations
of the Companys directors and Executive Officers and on confirmation that no Form 5 was required
to be filed, we believe that all reports required by Section 16(a) of the Exchange Act to be filed
by its directors, Executive Officers and greater than ten (10%) percent owners during the last
fiscal year were filed on time.
Code of Conduct for Officers and Employees and Code of Business Conduct and Ethics for Directors
The Company has a Code of Conduct that applies to all of our officers and employees as well as
a Code of Business Conduct and Ethics that applies specifically to the members of the Board of
Directors. The directors are surveyed annually regarding their compliance with the policies as set
forth in the Code of Conduct for Directors. The Code of Conduct and the Code of Business Conduct
and Ethics for Directors are available on the Corporate Governance section of our website at
www.emisphere.com. The contents of our website are not incorporated herein by reference and
the website address provided in this Amendment is intended to be an inactive textual reference
only. The Company intends to disclose on its website any amendment to, or waiver of, a provision of
the Code of Conduct that applies to the Chief Executive Officer, Chief Financial Officer, or
Controller. Our Code of Conduct contains provisions that apply to our Chief Executive Officer,
Chief Financial Officer and all other finance and accounting personnel. These provisions comply
with the requirements of a company code of ethics for financial officers that were promulgated by
the SEC pursuant to the Exchange Act.
Other Information
Certain information responsive to this Item 10 appears below in Item 13. Certain
Relationships and Related Transactions, and Director Independence.
ITEM 11. EXECUTIVE COMPENSATION
Summary Compensation Table 2008 and 2007
The following table sets forth information regarding the aggregate compensation Emisphere paid
during 2008 and 2007 to our Principal Executive Officer, our Principal Financial Officer, and the
two other highest paid Executive Officers, as well as one other officer who would have been
included had he been employed at the end of 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option |
|
All Other |
|
|
Name and Principal |
|
|
|
|
|
Salary |
|
Bonus |
|
Stock |
|
Awards |
|
Compensation |
|
|
Position |
|
Year |
|
($) |
|
($) |
|
Awards ($) |
|
($) (1) |
|
($) |
|
Total ($) |
|
Michael V.
Novinski,
President and CEO |
|
|
2008 |
|
|
|
554,231 |
|
|
|
357,123 |
(2) |
|
|
|
|
|
|
744,001 |
|
|
|
18,000 |
(3) |
|
|
1,673,355 |
|
|
|
|
2007 |
|
|
|
359,615 |
|
|
|
|
|
|
|
|
|
|
|
1,286,689 |
|
|
|
11,077 |
(3) |
|
|
1,657,381 |
|
Michael R. Garone,
VP, Chief Financial
Officer and
Corporate Secretary
(4) |
|
|
2008 |
|
|
|
231,794 |
|
|
|
|
|
|
|
|
|
|
|
51,648 |
|
|
|
|
|
|
|
283,417 |
|
|
|
|
2007 |
|
|
|
78,731 |
|
|
|
|
|
|
|
|
|
|
|
21,530 |
|
|
|
|
|
|
|
100,261 |
|
M. Gary I. Riley
DVM, PhD, VP of
Non-Clinical
Development and
Applied Biology (6) |
|
|
2008 |
|
|
|
267,039 |
|
|
|
40,000 |
(5) |
|
|
|
|
|
|
85,786 |
|
|
|
14,000 |
(6) |
|
|
406,825 |
|
|
|
|
2007 |
|
|
|
40,769 |
|
|
|
|
|
|
|
|
|
|
|
14,283 |
|
|
|
45,060 |
(6) |
|
|
100,112 |
|
Nicholas J. Hart,
VP,
Strategy and
Development (7) |
|
|
2008 |
|
|
|
104,308 |
|
|
|
16,872 |
(8) |
|
|
|
|
|
|
16,261 |
|
|
|
|
|
|
|
137,441 |
|
Paul Lubetkin,
Former VP, General
Counsel and
Corporate Secretary
(9) |
|
|
2008 |
|
|
|
220,048 |
|
|
|
|
|
|
|
|
|
|
|
37,860 |
|
|
|
|
|
|
|
257,908 |
|
|
|
|
2007 |
|
|
|
81,731 |
|
|
|
|
|
|
|
|
|
|
|
18,679 |
|
|
|
20,833 |
(10) |
|
|
121,243 |
|
|
|
|
(1) |
|
The value listed in the above table represents the fair value of the options recognized
as expense under FAS 123R during 2008, including unvested options granted before 2007 and
those granted in 2008. Fair value is calculated as of the grant date using a
Black-Scholes-Merton (Black-Scholes) option-pricing model. The determination of the fair
value of share-based payment awards made on the date of grant is affected by our stock
price as well as assumptions regarding a number of complex and subjective variables. Our
assumptions in determining fair value are described in note 11 to our audited financial
statements for the year ended December 31, 2008, included in our Annual Report on Form
10-K. |
|
(2) |
|
Mr. Novinski was paid a bonus in 2008 for performance in 2007 in accordance with the
terms of his employment contract. |
|
(3) |
|
All other compensation for Mr. Novinski represents an allowance for the use of a
personal automobile in accordance with the terms of his employment contract. |
|
(4) |
|
Mr. Garone was appointed Corporate Secretary effective October 24, 2008. |
|
(5) |
|
In accordance with the terms of his employment contract, Dr. Riley received a signing
bonus, payable during 2008, when he joined the Company. |
|
(6) |
|
All other compensation for Mr. Riley represents payments for relocation expenses. |
|
(7) |
|
Mr. Hart accepted the position as Vice President, Strategy and Development effective
July 28, 2008. |
|
(8) |
|
Mr. Hart received a signing bonus when he joined the Company. |
|
(9) |
|
Mr. Lubetkin served as Vice President, General Counsel and Corporate Secretary from
September 4, 2007 through October 24, 2008. |
|
(10) |
|
All other compensation for Mr. Lubetkin represents payments for relocation expenses. |
Compensation Discussion and Analysis
Executive Summary
The discussion that follows outlines the compensation awarded to, earned by or paid to the
named executive officers of the Company including a review of the principal elements of
compensation, the objectives of the Companys compensation program, what the program is designed to
reward and why and how each element of compensation is determined.
In general, the Company operates in a marketplace where competition for talented executives is
significant. The Company is engaged in the long-term development of its technology and of drug
candidates, without the benefit of significant current revenues, and therefore its operations
require it to raise capital in order to continue its activities. Our operations entail special
needs and risks and require that the Company attempt to implement programs that promote strong
individual and group performance and retention of excellent employees. The Companys compensation
program for named executive officers consists of cash compensation as base salary, medical, basic
life insurance, long term disability, flexible spending accounts, paid time off, and defined
contribution retirement plans as well as long term equity incentives offered through stock option
plans. This program is developed in part by benchmarking against other companies in the
biotechnology/pharmaceutical sectors, as well as by the judgment and discretion of our Board.
Employee salaries are benchmarked against Radford survey information. Radford is part of the
Aon family brands. For more than 30 years, Radford has been the leading provider of compensation
market intelligence to the high-tech and life sciences industries. Radford emphasizes data
integrity and online access to data, tools and resources, as well as client service geared towards
life sciences. Radford includes more than 2,000 participating companies globally. Their services
offer full compensation consulting, reliable, current data analysis and reporting, customized data
for competitive insight, and web access to data via the Radford Network.
Discussion and Analysis
Objectives of the compensation and reward program The biopharmaceutical marketplace is
highly competitive and includes companies with far greater resources than ours. Our work involves
the difficult, unpredictable, and often slow development of our technology and of drug candidates.
Continuity of scientific knowledge, management skills, and relationships are often critical
success factors to our business. The objectives of our compensation program for named executive
officers is to provide competitive cash compensation, competitive health, welfare and defined
benefit retirement benefits as well as long-term equity incentives that offer significant reward
potential for the risks assumed and for each individuals contribution to the long-term performance
of the Company. Individual performance is measured against long-term strategic goals, short-term
business goals, scientific innovation, regulatory compliance, new business development, development
of employees, fostering of teamwork and other Emisphere values designed to build a culture of high
performance. These policies and practices are based on the principle that total compensation
should serve to attract and retain those executives critical to the overall success of Emisphere
and are designed to reward executives for their contributions toward business performance that is
designed to build and enhance stockholder value.
Elements of compensation and how they are determined The key elements of the executive
compensation package are base salary (as determined by the competitive market and individual
performance), the executive long term disability plan and other health and welfare benefits and
long-term incentive compensation in the form of periodic stock option grants. The base salary
(excluding payment for accrued but unused vacation) for the named executive officers for 2008
ranged from $230,000 for its Vice President and Chief Financial Officer to $550,000 for its
President and Chief Executive Officer. In determining the compensation for each named executive
officer, the Company generally considers (i) data from outside studies and proxy materials
regarding compensation of executive officers at companies believed to be comparable, (ii) the input
of other directors and the President and Chief Executive Officer (other than for his own
compensation) regarding individual performance of each named executive officer and
(iii) qualitative measures of Emispheres performance, such as progress in the development of the
Companys technology, the engagement of corporate partners for the commercial development and
marketing of products, effective corporate governance, fiscal responsibility, the success of
Emisphere in raising funds necessary to conduct research and development, and the pace at which the
Company continues to advance its technologies in various clinical trials. Our board of directors
and Compensation Committees consideration of these factors is subjective and informal. However,
in general, it has determined that the compensation for executive officers should be competitive
with market data reflected within the 50th-75th percentile of biotechnology
companies for corresponding senior executive positions. 2008 compensation levels were set in 2006
and were based in part by information received from executive compensation consultants, Pearl Myer
and Partners, based in New York, N.Y. Compensable factors benchmarked include market
capitalization, head count and location. While the Company has occasionally paid cash bonuses in
the past, there is no consistent annual cash bonus plan for named executive officers. When
considering the compensation of the Companys President and Chief Executive Officer, the Company
receives information and analysis prepared or secured by the Companys outside executive
compensation experts and survey data prepared by human resources management personnel as well as
any additional outside information it may have available.
The compensation program also includes periodic awards of stock options. The stock option
element is considered a long-term incentive that further aligns the interests of executives with
those of our stockholders and rewards long-term performance and the element of risk. Stock option
awards are made at the discretion of the Board of Directors based on its subjective assessment of
the individual contribution of the executive to the attainment of short and long-term Company
goals, such as collaborations with partners, attainment of successful milestones under such
collaborations and other corporate developments which advance the progress of our technology and
drug candidates. Option grants, including unvested grants, for our named executive officers range
from 75,000 for our current Vice President, Chief Financial Officer and Corporate Secretary; Vice
President of Non-Clinical Development and Applied Biology; and Vice President, Strategy and
Development, to 1,000,000 for President and Chief Executive Officer as indicated in the
accompanying tables. The only stock option grants to named executive officers in 2008 were made in
connection retaining the newly hired Vice President, Strategy and Development. With the exception
of grants made to the Companys President and Chief Executive Officer (described in Transactions
with Officers and Directors), the Companys policy with respect to stock options granted to
executives is that grant prices should be equal to the fair market value of the Common Stock on the
date of grant, that employee stock options should generally vest over a four or five-year period
and expire in ten years from date of grant, and
that options previously granted at exercise prices higher than the current fair market value should
not be re-priced. Once performance bonuses or awards are issued, there are currently no policies
in place to reduce, restate or otherwise adjust awards if the relevant performance measures on
which they are based are restated or adjusted. The Company has no policy to require its named
executive officers to hold any specific equity interest in the Company. The Company does not offer
its named executive officers any nonqualified deferred compensation, a defined benefit pension
program or any post retirement medical or other benefits.
Section 162(m) of the Internal Revenue Code of 1986, as amended, provides that compensation in
excess of $1,000,000 paid to the Chief Executive Officer or to any of the other four most highly
compensated executive officers of a publicly held company will not be deductible for federal income
tax purposes, unless such compensation is paid pursuant to one of the enumerated exceptions set
forth in Section 162(m). The Companys primary objective in designing and administering its
compensation policies is to support and encourage the achievement of the Companys long-term
strategic goals and to enhance stockholder value. In general, stock options granted under the
Companys 2000 and 2007 Stock Option Plans are intended to qualify under and comply with the
performance based compensation exemption provided under Section 162(m) thus excluding from the
Section 162(m) compensation limitation any income recognized by executives at the time of exercise
of such stock options. Because salary and bonuses paid to our Chief Executive Officer and four
most highly compensated executive officers have been below the $1,000,000 threshold, the
Compensation Committee has elected, at this time, to retain discretion over bonus payments, rather
than to ensure that payments of salary and bonus in excess of $1,000,000 are deductible. The
Compensation Committee intends to review periodically the potential impacts of Section 162(m) in
structuring and administering the Companys compensation programs.
The Company has an employment contract with its current President and Chief Executive Officer,
Michael V. Novinski as described under Transactions with Executive Officers and Directors. Mr.
Novinskis employment contract called for compensation and specific benefits that were negotiated
at the time of execution, including expenses of an automobile up to $1,500 per month and
reimbursement for life insurance up to $15,000 per year. These additional benefits are not offered
to the other named executive officers. Mr. Novinskis contract also called for an annual cash
bonus up to $550,000 (based on a full calendar year). For 2008, in view of the financial situation
of the Corporation, the Compensation Committee, with the consent of Mr. Novinski, has agreed that
no bonus will be paid to Mr. Novinski pursuant to his employment agreement with the Corporation in
respect of the Corporations 2008 fiscal year; and that the committee may, in its sole discretion,
consider whether a special bonus should be paid to Mr. Novinski in 2009 following the successful
completion of a financing by the Corporation, and may make recommendations in respect thereto to
the full Board of Directors. Mr. Novinskis Employment Contract allows for severance payments to
Mr. Novinski in the event of certain terminations which call for payment of base salary plus bonus
(depending on the circumstances) plus the continuity of health and life insurance benefits for
specified time periods. In addition, certain unvested options would vest immediately upon such
termination. The events which would trigger such payment by the Company are defined in the
agreement.
Compensation Committee Report
The following Report of the Compensation Committee does not constitute soliciting material and
should not be deemed filed or incorporated by reference into any of our other filings under the
Securities Act of 1933 or the Exchange Act, except to the extent we specifically incorporate this
Report by reference therein.
The Compensation Committee operates under a written charter adopted by the Board of Directors.
The Compensation Committee charter can be found on our website at www.emisphere.com. The contents
of our website are not incorporated herein by reference and the website address provided in this
Amendment is intended to be an inactive textual reference only.
The Compensation Committee is responsible for the consideration of stock plans, performance
goals and incentive awards, and the overall coverage and composition of the compensation
arrangements related to executive officers. The Compensation Committee may delegate any of the
foregoing duties and responsibilities to a subcommittee of the Compensation Committee consisting of
not less than two members of the committee. The Compensation Committee has the authority to
retain, at the expense of the Company, such outside counsel, experts and other advisors as deemed
appropriate to assist it in the full performance of its functions. The Companys Chief
Executive Officer is involved in making recommendations to the Compensation Committee for
compensation of executive officers (except for himself) as well as recommending compensation levels
for directors.
Our executive compensation program is administered by the Compensation Committee of the Board
of Directors. The Compensation Committee, which is composed of non-employee independent directors,
is responsible for reviewing with Company management and approving compensation policy and all
forms of compensation for executive officers and directors in light of the Companys current
business environment and the Companys strategic objectives. In addition, the Compensation
Committee acts as the administrator of the Companys stock option plans. The Compensation
Committees practices include reviewing and establishing executive officers compensation to ensure
that base pay and incentive compensation are competitive to attract and retain qualified executive
officers, and to provide incentive systems reflecting both financial and operating performance, as
well as an alignment with stockholder interests. These policies are based on the principle that
total compensation should serve to attract and retain those executives critical to the overall
success of Emisphere and should reward executives for their contributions to the enhancement of
stockholder value.
The Compensation Committee has reviewed the Compensation Discussion and Analysis presented
herein under Compensation Plans with the management of the Company. Based on that review and
discussion, the Compensation Committee recommended to the Board of Directors that the Compensation
Discussion and Analysis be included in this Amendment No. 1 to the Form 10-K of the Company.
The Members of the Compensation Committee
Michael Weiser, M.D., Ph.D. (chairman)
Kenneth I. Moch
Mark H. Rachesky, M.D.
Transactions With Executive Officers and Directors
Employment Agreement with Michael V. Novinski, President and Chief Executive Officer
On April 6, 2007, the Company entered into an Employment Agreement with Michael V. Novinski,
setting forth the terms and conditions of his employment as President and Chief Executive of the
Company. The Agreement is for a term of three years, renewable annually thereafter. Under the
Agreement, Mr. Novinski will receive a base salary of $550,000 per year, less applicable local,
state and federal withholding taxes. Mr. Novinski was also granted options to purchase 1,000,000
shares of the Companys Common Stock; the exercise price for 500,000 of the shares was $3.19, the
fair market value of the Common Stock on the date of grant, and the exercise price for the
remaining 500,000 shares is equal to two times the fair market value of the Common Stock on the
date of grant. At December 31, 2008, options to purchase 500,000 shares are vested, another
twenty-five percent (250,000 shares) will vest on the second, and third anniversaries of the date
of grant respectively. In addition, he will be eligible for an annual cash bonus up to $550,000
(based on a full calendar year). For 2008, in view of the financial situation of the Corporation,
the Compensation Committee, with the consent of Mr. Novinski, has agreed that no bonus will be paid
to Mr. Novinski pursuant to his employment agreement with the Corporation in respect of the
Corporations 2008 fiscal year; and that the committee may, in its sole discretion, consider
whether a special bonus should be paid to Mr. Novinski in 2009 following the successful completion
of a financing by the Corporation, and may make recommendations in respect thereto to the full
Board of Directors.
In addition, Mr. Novinskis Employment Agreement provides that he will be provided (a) four
weeks paid vacation, a car allowance of $18,000 per year (up to $1,500 per month), and
reimbursement of up to $15,000 of life insurance payments per year. If Emisphere terminates Mr.
Novinski without Cause or if Mr. Novinski terminates his employment for Good Reason (each
capitalized term as defined in the Employment Agreement), subject to certain conditions, Mr.
Novinski will be entitled to (a) payment of salary through the termination date, (b) payment of
pro-rata bonus based on the target bonus for the year of termination, (c) payment equal to nine
months of salary, (d) acceleration of the next two scheduled vesting dates of the above option
grants, (all options will be accelerated in the event of a Change in Control as defined in the
Employment Agreement), (e) continued participation in
Emispheres health benefit plan for up to 12 months, and (f) payment of benefits or other amounts
earned, accrued, or owning under Emispheres plans or programs.
If Emisphere terminates Mr. Novinskis employment due to Death or Long-Term Disability (each
capitalized term as defined in the Employment Agreement), subject to certain conditions, Mr.
Novinski will be entitled to (a) payment of salary through the termination date, (b) payment of
pro-rata bonus based on the target bonus for the year of termination, (c) acceleration of the
scheduled vesting dates of the above option grants, (d) continued participation in Emispheres
health benefit plan for up to 12 months, and (e) payment of benefits or other amounts earned,
accrued or owning under Emispheres plans or programs.
Agreement with M. Gary I. Riley, Vice President on Non-Clinical Development and Applied Biology
The Company has an agreement with M. Gary I. Riley by which in the event that there is a
Change in Control during executives first twenty four months (two years) of employment at
Emisphere resulting in termination of employment during that twenty four month period, a severance
amount, equivalent to one years base salary (excluding bonus and relocation assistance) will be
provided to the executive. In the event there is a Change in Control after executives first twenty
four months of employment, a severance amount, equivalent to six months base salary will be
provided to him.
In addition, in the event that there is a Change in Control during his employment at Emisphere
resulting in termination of employment, subject to approval by the Board of Directors, he shall
receive, in addition to the options already vested, immediate vesting of all remaining options as
set forth in the Plan.
Agreement with Nicholas J. Hart, Vice President, Strategy and Development
The Company has an agreement with Nicholas J. Hart by which in the event that there is a
Change in Control during executives term of employment at Emisphere resulting in termination of
employment, a severance amount, equivalent to six months base salary (excluding bonus) will be
provided to the executive.
In addition, in the event that there is a Change in Control during his employment at Emisphere
resulting in termination of employment, subject to approval by the Board of Directors, he shall
receive, in addition to the options already vested, immediate vesting of all remaining options as
set forth in the Plan.
Employment Agreement with Michael M. Goldberg, former President and Chief Executive Officer
In April 2005, the Company entered into an amended and restated employment agreement with its
then Chief Executive Officer, Dr. Michael M. Goldberg, for services through July 31, 2007. On
January 16, 2007, the Board of Directors terminated Dr. Goldbergs services. On April 26, 2007,
the Board of Directors held a special hearing at which it determined that Dr. Goldbergs
termination was for cause. On March 22, 2007, Dr. Goldberg, through his counsel, filed a demand
for arbitration asserting that his termination was without cause and seeking $1,048,000 plus
attorneys fees, interest, arbitration costs and other relief alleged to be owed to him in
connection with his employment agreement with the Company.
Dr. Goldbergs employment agreement provides, among other things, that in the event he is
terminated without cause, Dr. Goldberg would be paid his base salary plus bonus, if any, monthly
for a severance period of eighteen months or, in the event of a change of control, twenty-four
months, and he would also be entitled to continued health and life insurance coverage during the
severance period and all unvested stock options and restricted stock awards would immediately vest
in full upon such termination. Dr. Goldbergs employment agreement provided that in the event he
is terminated with cause, he will receive no additional compensation.
During the year ended December 31, 2007, the Company accrued costs to settle this matter. No
settlement has been reached and the dispute continues. In February 2008, the Company received $0.5
million as a result of a cancellation of a split dollar life insurance policy on Dr. Goldberg. Dr.
Goldberg claimed approximately $0.2 million was due him as a return of policy premium. In June
2008, Dr. Goldberg commenced a separate lawsuit in the New York State Supreme Court (New York
County) claiming that the Company breached his employment agreement by not remitting to Dr.
Goldberg that portion of the cash value of the life insurance policy. On January
29, 2009, after transfer from the New York State Supreme Court (New York County) to an independent
arbitrator, the Company received a finding from such arbitrator awarding a partial summary judgment
to Dr. Goldberg for compensatory damages in an amount equal to $240,101. The company paid Dr.
Goldberg such amount on February 5, 2009. All remaining claims were deferred by the Arbitrator
pending further proceedings between the parties. The Company believes the remaining claims are
without merit and will vigorously defend itself against Dr. Goldbergs claims.
Agreements with other former Officers
The Company had an agreement with Steven M. Dinh, formerly VP of Research Technology and
Development, by which in the event that there is a Change in Control resulting in his
termination, or a material lessening in job responsibilities and he elects to terminate his
employment within 6 months after such change, he shall receive, in addition to the options already
vested, (a) a lump sum amount equal to his annual base salary at the time his employment ends, less
applicable taxes and deductions; (b) immediate vesting of all remaining options as stipulated by
the Plan; and (c) other benefits earned by him in accordance with Emispheres standard policies
(i.e. accrued vacation). In addition, if Mr. Dinh is terminated for any reason other than cause,
he will receive a lump sum amount equal to his annual base salary at the time his employment ends,
less applicable taxes and deductions. Mr. Dinh was terminated on August 31, 2007. Pursuant to an
Agreement and General Release, Mr. Dinh received severance pay of $10,397 from September 3, 2007
through February 28, 2008, less lawful deductions, a portion of medical insurance premiums paid by
Emisphere at same levels he had prior to separation, and certain outplacement services. In
addition, the vesting of certain options granted to Mr. Dinh was accelerated to be fully vested on
August 31, 2007 and such options will remain exercisable for the term of such grants.
The Company terminated Shepard Goldberg, Senior Vice President of Operations as of June 8,
2007. Pursuant to an Agreement and General Release, Mr. Goldberg received severance pay of $10,496
bi-weekly from June 11, 2007-December 31, 2007, less lawful deductions, a portion of medical
insurance premiums paid by Emisphere at same levels he had prior to separation, and certain
outplacement services. In addition, the vesting of certain options granted to Mr. Goldberg was
accelerated to be fully vested on June 8, 2007 and such options will remain exercisable through
March 30, 2008.
The Company terminated Lewis H. Bender, Chief Technology Officer, as of December 7, 2007.
Pursuant to an Agreement and General Release, Mr. Bender received severance pay of $13,677
bi-weekly from December 10, 2007-June 6, 2008, less lawful deductions, a portion of medical
insurance premiums paid by Emisphere at same levels he had prior to separation, and certain
outplacement services. In addition, all of Mr. Benders option agreements will continue in full
force and effect in accordance with their original terms.
Grants Of Plan-Based Awards 2008
The following table sets forth information regarding grants of plan-based awards in 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Other |
|
|
|
|
|
|
|
|
|
|
Option |
|
|
|
|
|
|
|
|
|
|
Awards: |
|
Exercise or |
|
|
|
|
|
|
|
|
Number of |
|
Base Price of |
|
Grant Date |
|
|
|
|
|
|
Securities |
|
Option |
|
Fair Value of |
|
|
|
|
|
|
Underlying |
|
Awards |
|
Option |
Name |
|
Grant Date |
|
Options (#) |
|
($/Sh) |
|
Awards |
|
Nicholas J. Hart |
|
|
7/14/2018 |
|
|
|
75,000 |
|
|
$ |
2.71 |
|
|
$ |
173,550 |
|
Outstanding Equity Awards at Fiscal Year-End 2008
The following table sets forth information as to the number and value of unexercised options
held by the Executive Officers named above as of December 31, 2008. There are no outstanding stock
awards with executive officers:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity Incentive |
|
|
|
|
|
|
|
|
|
|
Number of |
|
Plan Awards: |
|
|
|
|
|
|
Number of |
|
Securities |
|
Number of |
|
|
|
|
|
|
Shares |
|
Underlying |
|
Securities |
|
|
|
|
|
|
Underlying |
|
Unexercised |
|
Underlying |
|
|
|
|
|
|
Unexercised |
|
Unearned |
|
Unexercised |
|
Option |
|
Option |
|
|
Options (#) |
|
Options (#) |
|
Unearned |
|
Exercise Price |
|
Expiration |
Name |
|
Exercisable |
|
Unexercisable |
|
Options (#) |
|
($) |
|
Date |
|
Michael V.
Novinski, |
|
|
250,000 |
|
|
|
250,000 |
(1) |
|
|
|
|
|
$ |
3.19 |
|
|
|
4/6/2017 |
|
President and CEO |
|
|
250,000 |
|
|
|
250,000 |
(2) |
|
|
|
|
|
$ |
6.38 |
|
|
|
4/6/2017 |
|
Michael R. Garone,VP,
Chief Financial
Officer and
Corporate Secretary |
|
|
15,000 |
|
|
|
60,000 |
(3) |
|
|
|
|
|
$ |
4.03 |
|
|
|
8/29/2017 |
|
M. Gary I. Riley,
DVM, PhD. VP of
non-Clinical
Development and
Applied Biology |
|
|
25,000 |
|
|
|
50,000 |
(4) |
|
|
|
|
|
$ |
4.02 |
|
|
|
11/6/2017 |
|
Nicholas J. Hart,
Vice President,
Strategy and
Development |
|
|
|
|
|
|
75,000 |
(5) |
|
|
|
|
|
$ |
2.71 |
|
|
|
7/14/2018 |
|
Paul Lubetkin,
Former VP, General
Counsel and
Corporate Secretary |
|
|
15,000 |
(6) |
|
|
|
|
|
|
|
|
|
$ |
4.37 |
|
|
|
9/4/2017 |
|
|
|
|
(1) |
|
125,000 exercisable on each 4/6/2009 and 4/6/2010, respectively |
|
(2) |
|
125,000 exercisable on each 4/6/2009 and 4/6/2010, respectively |
|
(3) |
|
15,000 exercisable on each 8/29/2009, 8/29/2010, 8/29/2011 and 8/29/2012, respectively |
|
(4) |
|
25,000 exercisable on each 11/6/2009 and 11/6/2010, respectively |
|
(5) |
|
15,000 exercisable on each 7/14/2009, 7/14/2010, 7/14/2011, 7/14/2012 and 7/14/2013,
respectively |
|
(6) |
|
Mr. Lubetkin served as Vice President, General Counsel and Corporate Secretary from
September 4, 2007 through October 24, 2008; the vested portion of his options award expired
January 22, 2009 in accordance with the terms of the Plan. |
Option Exercises and Stock Vested 2008
There were no stock options exercised by Executive Officers during 2008.
Compensation of Non-Employee Directors
A director who is a full-time employee of the Company receives no additional compensation for
services provided as a director. It is the Companys policy to provide competitive compensation and
benefits necessary to attract and retain high quality non-employee directors and to encourage
ownership of Company stock to further align their interests with those of stockholders. The
following represents the compensation of the non-employee members of the Board of Directors:
|
|
|
Under the 2007 Stock Award and Incentive Plan, each non-employee director received, on
the date of each regular annual stockholders meeting, a stock option to purchase 7,000
shares of our Common Stock. The stock options vest on the six month anniversary of the
grant date provided the director continuously serves as a director from the grant date
through such vesting date. Notwithstanding the foregoing, any director who holds any stock
options granted before April 1, 2004 which remain unvested was ineligible to receive the
annual 7,000-share stock option grant described in this paragraph unless and until all such
prior options had vested. Stock options granted in 2008 have a stated expiration date of
ten years after the date of grant, and are subject to accelerated vesting upon a change in
control of Emisphere. If the holder of an option |
|
|
|
ceases to serve as a director, all previously granted options may be exercised to the extent
vested within six months after termination of directorship (one year if the termination is
by reason of death), except that, after April 1, 2004 (unless otherwise provided in an
option agreement), if a director becomes an emeritus director of Emisphere immediately
following his Board service, the vested options may be exercised for six months after
termination of service as an emeritus director. All unvested options expire upon
termination of Board service. |
|
|
|
In recognition of the roles and responsibilities of the Board of Directors and current
market data, the Board of Directors compensation includes an annual retainer of $20,000,
half of which is payable in cash and the balance of which had been payable in shares of
restricted stock granted under the Director Stock Plan on the date of each regular annual
stockholders meeting, provided the director is an eligible director on that date. The
number of shares of restricted stock was determined by dividing the cash portion of the
annual board retainer by the closing price of the Common Stock on the grant date. The
shares of restricted stock would vest on the date six months after the grant date provided
the director continuously serves as a director from the grant date through such vesting
date, subject to accelerated vesting upon a change in control of Emisphere. |
|
|
|
|
Additional committee and chairperson fees are paid as follows: |
|
o |
|
$3,000 annual committee retainer paid quarterly; |
|
|
o |
|
$1,000 per committee meeting fee, but only if the meeting exceeds 15
minutes and is not held on the same day as a board meeting; and |
|
|
o |
|
An additional $500 payable to the chairperson of each committee for
each committee meeting, but only if the meeting exceeds 15 minutes and is not held
on the same day as a board meeting. |
For each board meeting attended prior to April 1, 2004, non-employee directors had the right
to receive, under our Directors Deferred Compensation Stock Plan, shares of Common Stock, based on
a fee of $1,000 and the closing price of the Common Stock on the date of the meeting (the Annual
Board Retainer). Under that plan, Emisphere maintains a share account for each eligible
director and is obligated to issue the shares within six months of a directors retirement from the
board or other termination as a director. Through January 31, 2004, Dr. Carter has 355 shares in
accordance with the Directors Deferred Compensation Stock Plan, which will be available to him
following his termination of service to the Board of Directors. Mr. Pack, who passed away on
December 9, 2008, had 2,767 shares in accordance with the Directors Deferred Compensation Stock
Plan, which will be delivered to Mr. Packs estate in accordance therewith.
Director Compensation Table 2008
The table below represents the compensation paid to our non-employee directors during the year
ended December 31, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fees Earned |
|
|
|
|
|
Option |
|
All Other |
|
|
|
|
or Paid in |
|
Stock Awards |
|
Awards |
|
Compensation |
|
|
Name |
|
Cash ($) |
|
($) (1) |
|
($) (1) |
|
($) |
|
Total ($) |
|
Howard M. Pack |
|
|
23,000 |
|
|
|
2,084 |
|
|
|
1,751 |
|
|
|
|
|
|
|
26,835 |
|
Kenneth I. Moch (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stephen K. Carter,
M.D.(3) |
|
|
16,000 |
|
|
|
2,084 |
|
|
|
27,911 |
|
|
|
|
|
|
|
45,995 |
|
John D. Harkey, Jr. |
|
|
19,000 |
|
|
|
2,084 |
|
|
|
1,751 |
|
|
|
|
|
|
|
22,835 |
|
Michael M.
Goldberg, M.D(4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mark H. Rachesky,
M.D. |
|
|
16,000 |
|
|
|
2,084 |
|
|
|
1,114 |
|
|
|
|
|
|
|
19,198 |
|
Michael Weiser, M.D. |
|
|
17,000 |
|
|
|
2,084 |
|
|
|
1,751 |
|
|
|
|
|
|
|
20,835 |
|
|
|
|
(1) |
|
The value listed in the above table represents the fair value of the options recognized
as expense under FAS 123R during 2008, including unvested options granted before 2007 and
those granted in 2008. Fair value is calculated as of the grant date using a
Black-Scholes-Merton (Black-Scholes) option-pricing model. The determination of the fair |
|
|
|
|
|
value of share-based payment awards made on the date of grant is affected by our stock price
as well as assumptions regarding a number of complex and subjective variables. Our
assumptions in determining fair value are described in note 11 to our audited financial
statements for the year ended December 31, 2008, included in our Annual Report on Form 10-K. |
|
(2) |
|
Mr. Moch was appointed to the Board of Directors on December 23, 2008; as a result, Mr.
Moch did not receive an annual retainer, committee fees, option or stock awards during the
year ended December 31, 2008. |
|
(3) |
|
Dr. Carter resigned from the Board of Directors effective April 30, 2009. |
|
(4) |
|
Dr. Goldberg previously served as Chairman and Chief Executive Officer. His employment
was terminated on January 16, 2007. On April 26, 2007 the Board of Directors held a
special hearing at which it was determined that Dr. Goldbergs termination was for cause.
On March 22, 2007, Dr. Goldberg, through counsel, filed a demand for arbitration asserting
that his termination was without cause. Depending on the ultimate conclusion of this
arbitration, Dr. Goldberg may be entitled to additional options granted when he was Chief
Executive Officer. Accordingly, the outcome of the arbitration could also affect, among
other items disclosed or discussed in this Amendment, the number of shares available for
grant under the Companys option plans. Dr. Goldberg resigned from the Board of Directors
effective March 11, 2008. |
The following table summarizes the aggregate number of option awards and stock awards held by
each non-employee director at December 31, 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards |
|
Stock Awards |
|
|
|
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive Plan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of |
|
Awards: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Market |
|
|
Number of |
|
Securities |
|
Number of |
|
|
|
|
|
|
|
|
|
Number of |
|
value of |
|
|
Securities |
|
Underlying |
|
Securities |
|
|
|
|
|
|
|
|
|
Shares of |
|
shares or |
|
|
Underlying |
|
Unexercised |
|
Underlying |
|
|
|
|
|
|
|
|
|
units of |
|
units of |
|
|
Unexercised |
|
Unearned |
|
Unexercised |
|
Option |
|
Option |
|
stock that |
|
stock that |
|
|
Options (#) |
|
Options (#) |
|
Unearned |
|
Exercise |
|
Expiration |
|
have not |
|
have not |
Name |
|
Exercisable |
|
Unexercisable |
|
Options (#) |
|
Price ($) |
|
Date |
|
vested (#) |
|
vested ($) |
|
Howard M. Pack(1) |
|
|
21,000 |
|
|
|
|
|
|
|
|
|
|
|
41.06 |
|
|
|
4/28/2010 |
|
|
|
2,638 |
|
|
|
2,084 |
|
|
|
|
35,000 |
|
|
|
|
|
|
|
|
|
|
|
13.00 |
|
|
|
5/10/2012 |
|
|
|
|
|
|
|
|
|
|
|
|
21,000 |
|
|
|
|
|
|
|
|
|
|
|
2.89 |
|
|
|
4/28/2013 |
|
|
|
|
|
|
|
|
|
|
|
|
7,000 |
|
|
|
|
|
|
|
|
|
|
|
8.97 |
|
|
|
5/26/2016 |
|
|
|
|
|
|
|
|
|
|
|
|
7,000 |
|
|
|
|
|
|
|
|
|
|
|
3.76 |
|
|
|
4/20/2017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,000 |
|
|
|
|
|
|
|
3.79 |
|
|
|
8/8/2018 |
|
|
|
|
|
|
|
|
|
Kenneth I. Moch(2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stephen K.
Carter, M.D. |
|
|
35,000 |
|
|
|
|
|
|
|
|
|
|
|
5.75 |
|
|
|
12/11/2013 |
|
|
|
2,638 |
|
|
|
2,084 |
|
|
|
|
|
|
|
|
7,000 |
|
|
|
|
|
|
|
3.79 |
|
|
|
8/8/2018 |
|
|
|
|
|
|
|
|
|
John D.
Harkey, Jr. |
|
|
7,000 |
|
|
|
|
|
|
|
|
|
|
|
8.97 |
|
|
|
5/26/2016 |
|
|
|
2,638 |
|
|
|
2,084 |
|
|
|
|
7,000 |
|
|
|
|
|
|
|
|
|
|
|
3.76 |
|
|
|
4/20/2017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,000 |
|
|
|
|
|
|
|
3.79 |
|
|
|
8/8/2018 |
|
|
|
|
|
|
|
|
|
Mark H.
Rachesky, M.D. |
|
|
7,000 |
|
|
|
|
|
|
|
|
|
|
|
3.76 |
|
|
|
4/20/2017 |
|
|
|
2,638 |
|
|
|
2,084 |
|
|
|
|
|
|
|
|
7,000 |
|
|
|
|
|
|
|
3.79 |
|
|
|
8/8/2018 |
|
|
|
|
|
|
|
|
|
Michael Weiser, M.D. |
|
|
7,000 |
|
|
|
|
|
|
|
|
|
|
|
8.97 |
|
|
|
5/26/2016 |
|
|
|
2,638 |
|
|
|
2,084 |
|
|
|
|
7,000 |
|
|
|
|
|
|
|
|
|
|
|
3.76 |
|
|
|
4/20/2017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,000 |
|
|
|
|
|
|
|
3.79 |
|
|
|
8/8/2018 |
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Mr. Pack passed away on December 9, 2008. Mr. Packs unvested options and shares vested in
accordance with the plan and will be delivered to his estate. |
|
(2) |
|
Mr. Moch was appointed to the Board of Directors on December 23, 2008; as a result, Mr. Moch
did not receive option or stock awards during the year ended December 31, 2008. |
|
|
|
ITEM 12. |
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER
MATTERS |
Securities Available for Future Issuance under Equity Plans
The following table provides information as of December 31, 2008 about the Common Stock that
may be issued upon the exercise of options granted to employees, consultants or members of our
Board of Directors under
our existing equity compensation plans, including the 1991 Stock Option Plan, 1995 Stock Option
Plan, 2000 Stock Option Plan, the 2002 Broad Based Plan, the 2007 Stock Award and Incentive Plan
(collectively the Plans) the Stock Incentive Plan for Outside Directors and the Directors
Deferred Compensation Plan:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a) |
|
|
|
|
|
|
(c) |
|
|
|
Number of |
|
|
(b) |
|
|
Number of securities |
|
|
|
securities to be |
|
|
Weighted |
|
|
remaining available for |
|
|
|
issued upon |
|
|
average |
|
|
Future issuance under |
|
|
|
exercise of |
|
|
exercise price |
|
|
equity compensation plans |
|
|
|
outstanding |
|
|
of outstanding |
|
|
(excluding securities |
|
Plan Category |
|
options |
|
|
options |
|
|
reflected in column (a)) |
|
Equity Compensation
Plans Approved by
Security Holders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Plans |
|
|
2,032,854 |
|
|
$ |
8.30 |
|
|
|
2,757,859 |
|
Stock Incentive
Plan for
Outside
Directors |
|
|
156,000 |
|
|
|
13.38 |
|
|
|
|
|
Directors
Deferred
Compensation
Plan |
|
|
|
|
|
|
|
|
|
|
3,122 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity Compensation
Plans not approved
by Security Holders
(1) |
|
|
20,000 |
|
|
|
14.84 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
2,208,854 |
|
|
$ |
8.72 |
|
|
|
2,760,981 |
|
|
|
|
(1) |
|
Our Board of Directors has granted options which are currently outstanding for a former
consultant. The Board of Directors determines the number and terms of each grant (option exercise
price, vesting and expiration date). These grants were made on 7/12/2001, 7/12/2002 and 7/14/2003. |
Voting Securities and Principal Holders Thereof
At the close of business on the Record Date, there were approximately 30,341,078 shares of
Common Stock outstanding and entitled to vote. The presence, either in person or by proxy, of
persons entitled to vote a majority of our outstanding Common Stock is necessary to constitute a
quorum for the transaction of business at the Annual Meeting. Abstentions and broker non-votes are
counted for purposes of determining a quorum. Abstentions are counted as if they were no votes
in tabulations of the votes cast, whereas broker non-votes, are not considered as having voted for
the purposes of determining the outcome of a vote. Holders of Common Stock have one vote for each
share on any matter that may be presented for consideration and action by the stockholders at the
Annual Meeting.
Common Stock Ownership by Directors and Executive Officers and Principal Holders
Directors and Executive Officers
The following table sets forth certain information, as of April 1, 2009, regarding the
beneficial ownership of the Common Stock by (i) each director, including the Director Nominees;
(ii) each Executive Officer; and (iii) all of our directors and Executive Officers as a group. The
number of shares beneficially owned by each director or Executive Officer is determined under the
rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any
other purpose. Under these rules, beneficial ownership includes any shares as to which the
individual has the sole or shared voting power (which includes power to vote, or direct the voting
of, such security) or investment power (which includes power to dispose of, or direct the
disposition of, such security). In
computing the number of shares beneficially owned by a person
and the percentage ownership of that person, shares of Common Stock subject to options, warrants or
convertible notes held by that person that are currently exercisable
or convertible into Common Stock or will become exercisable or convertible into Common Stock within
60 days after April 1, 2009 are deemed outstanding, while such shares are not deemed outstanding
for purposes of computing percentage ownership of any other person. Unless otherwise indicated,
all persons named as beneficial owners of Common Stock have sole voting power and sole investment
power with respect to the shares indicated as beneficially owned:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Shares |
|
Common Shares |
|
Percent |
Name and Address (a) |
|
Beneficially Owned |
|
Underlying Options |
|
Of Class |
|
|
(b) |
|
|
|
|
Michael V. Novinski |
|
|
565,000 |
|
|
|
500,000 |
|
|
|
1.8 |
% |
Michael R. Garone |
|
|
15,000 |
|
|
|
15,000 |
|
|
|
* |
|
Paul Lubetkin (c) |
|
|
|
|
|
|
|
|
|
|
* |
|
Gary Riley, DVM, Ph.D. |
|
|
75,000 |
|
|
|
25,000 |
|
|
|
* |
|
Nicholas Hart |
|
|
|
|
|
|
|
|
|
|
* |
|
Mark H. Rachesky, M.D. |
|
|
11,393,247 |
(d) |
|
|
6,722,587 |
(e) |
|
|
30.7 |
% |
Howard M. Pack (f) |
|
|
202,599 |
|
|
|
91,000 |
|
|
|
* |
|
Kenneth I. Moch (g) |
|
|
|
|
|
|
|
|
|
|
* |
|
Stephen Carter, M.D.(h) |
|
|
50,824 |
|
|
|
42,000 |
|
|
|
* |
|
Michael Weiser, M.D. |
|
|
24,775 |
|
|
|
21,000 |
|
|
|
* |
|
John D. Harkey, Jr. |
|
|
24,775 |
|
|
|
21,000 |
|
|
|
* |
|
All directors and executive officers as a group |
|
|
12,351,220 |
|
|
|
7,437,587 |
|
|
|
32.7 |
% |
(a) |
|
Unless otherwise specified, the address of each beneficial owner is c/o Emisphere
Technologies, Inc., 240 Cedar Knolls Road, Suite 200, Cedar Knolls, New Jersey 07927. |
|
(b) |
|
The number of shares set forth for each Director and Executive Officer consists of
direct and indirect ownership of shares, including stock options, deferred common share
units, restricted stock and, in the case of Dr. Rachesky, shares of Common Stock that can
be obtained upon conversion of convertible notes and exercise of warrants, as further
described in footnote (d) below. |
|
(c) |
|
Mr. Lubetkin served as Vice President, General Counsel and Corporate Secretary from
September 4, 2007 through
October 24, 2008. |
|
(d) |
|
This number consists of: |
|
o |
|
4,670,660 Shares of Common Stock held for the accounts of the following
entities: |
|
§ |
|
3,123,626 shares held for the account of MHR Capital Partners Master
Account LP (Master Account) |
|
|
§ |
|
424,818 shares held for the account of MHR Capital Partners (100) LP
(Capital Partners (100)) |
|
|
§ |
|
317,369 shares held for the account of MHR Institutional Partners II LP
(Institutional Partners II) |
|
|
§ |
|
799,549 shares held for the account of MHR Institutional Partners IIA LP
(Institutional Partners IIA) |
|
|
§ |
|
5,298 shares held directly by Mark H. Rachesky, M.D. |
|
o |
|
5,612,929 shares of Common Stock that can be obtained by the following
entities upon conversion of the Convertible Notes, including 250,333 shares of
Common Stock issuable to the following entities as payment for accrued but unpaid
interest on the Convertible Notes since the most recent interest payment date
(December 31, 2008) through the date that is 60 days after April 1, 2009: |
|
§ |
|
1,130,262 shares held by Master Account |
|
|
§ |
|
154,566 shares held by Capital Partners (100) |
|
|
§ |
|
1,229,817 shares held by Institutional Partners II |
|
|
§ |
|
3,098,284 shares held by Institutional Partners IIA |
|
o |
|
1,095,658 shares of Common Stock that can be obtained by the following
entities upon exercise of warrants: |
|
§ |
|
836,896 held by Master Account |
|
|
§ |
|
115,961 held by Capital Partners (100) |
|
|
§ |
|
40,576 held by Institutional Partners II |
|
|
§ |
|
102,225 held by Institutional Partners IIA |
|
o |
|
7,000 shares of Common Stock that can be obtained by Dr. Rachesky upon
the exercise of currently vested stock options at a price of $3.76 per share |
|
o |
|
7,000 shares of Common Stock that can be obtained by Dr. Rachesky upon
the exercise of currently vested stock options at a price of $3.79 per share |
|
|
MHR Advisors LLC (Advisors) is the general partner of each of Master Account and Capital
Partners (100), and, in such capacity, may be deemed to beneficially own the shares of
Common Stock held for the accounts of each of Master Account and Capital Partners (100).
MHR Institutional Advisors II LLC (Institutional Advisors II) is the general partner of
each of Institutional Partners II and Institutional Partners IIA, and, in such capacity,
may be deemed to beneficially own the shares of Common Stock held for the accounts of each
of Institutional Partners II and Institutional Partners IIA. MHR Fund Management LLC
(Fund Management) is a Delaware limited liability company that is an affiliate of and has
an investment management agreement with Master Account, Capital Partners (100),
Institutional Partners II and Institutional Partners IIA, and other affiliated entities,
pursuant to which it has the power to vote or direct the vote and to dispose or to direct
the disposition of the shares of Common Stock reported herein and, accordingly, Fund
Management may be deemed to beneficially own the shares of Common Stock reported herein
which are held for the account of each of Master Account, Capital Partners (100),
Institutional Partners II and Institutional Partners IIA. Dr. Rachesky is the managing
member of Advisors, Institutional Advisors II, and Fund Management, and, in such capacity,
may be deemed to beneficially own the shares of Common Stock held for the accounts of each
of Master Account, Capital Partners (100), Institutional Partners II and Institutional
Partners IIA. |
|
(e) |
|
This number consists of (i) 5,612,929 shares of Common Stock that can be obtained by
Master Account, Capital Partners (100), Institutional Partners II and Institutional
Partners IIA upon conversion of the Convertible Notes, (ii) 1,095,658 shares of Common
Stock that can be obtained by Master Account, Capital Partners (100), Institutional
Partners II and Institutional Partners IIA upon exercise of warrants, and (iii) 14,000
share of Common Stock that can be obtained by Dr. Rachesky upon the exercise of currently
vested stock options. |
|
(f) |
|
Howard M. Pack passed away on December 9, 2008. |
|
(g) |
|
Kenneth I. Moch was appointed to the Board of Directors on December 23, 2008. |
|
(h) |
|
Dr. Carter resigned from the Board of Directors effective April 30, 2009. |
Principal Holders of Common Stock
The following table sets forth information regarding beneficial owners of more than five (5%)
percent of the outstanding shares of Common Stock as of April 1, 2009:
|
|
|
|
|
|
|
|
|
|
|
Number of Shares |
|
|
|
|
|
|
Beneficially |
|
|
Percent |
|
Name and Address |
|
Owned |
|
|
Of Class (a) |
|
Brandon Fradd
|
|
|
2,194,441 |
(b) |
|
|
7.2 |
% |
68 Jane Street
New York, NY 10014 |
|
|
|
|
|
|
|
|
Mark H. Rachesky, M.D.
|
|
|
11,393,247 |
(c) |
|
|
30.7 |
% |
40 West 57th Street, 24th Floor
New York, NY 10019 |
|
|
|
|
|
|
|
|
|
|
|
(a) |
|
Applicable percentage ownership is based on 30,341,078 shares of Common Stock
outstanding as of April 1, 2009. In computing the number of shares beneficially owned by a
person and the percentage ownership of that person, shares of Common Stock subject to
options, warrants or convertible notes held by that person that are currently exercisable
or convertible into Common Stock or will become exercisable or convertible into Common
Stock within 60 days after April 1, 2009 are deemed outstanding, while such shares are not
deemed outstanding for purposes of computing percentage ownership of any other person. |
|
(b) |
|
Information based on Amendment Number 2 to Schedule 13-G filed with the SEC on February
17, 2009. |
|
(c) |
|
This number consists of: |
|
o |
|
4,670,660 Shares of Common Stock held for the accounts of the following
entities: |
|
§ |
|
3,123,626 shares held for the account of MHR Capital Partners Master
Account LP (Master Account) |
|
|
§ |
|
424,818 shares held for the account of MHR Capital Partners (100) LP
(Capital Partners (100)) |
|
|
§ |
|
317,369 shares held for the account of MHR Institutional Partners II LP
(Institutional Partners II) |
|
§ |
|
799,549 shares held for the account of MHR Institutional Partners IIA LP
(Institutional Partners IIA) |
|
|
§ |
|
5,298 shares held directly by Mark H. Rachesky, M.D. |
|
o |
|
5,612,929 shares of Common Stock that can be obtained by the following
entities upon conversion of the Convertible Notes, including 250,333 shares of
Common Stock issuable to the following entities as payment for accrued but unpaid
interest on the Convertible Notes since the most recent interest payment date
(December 31, 2008) through the date that is 60 days after April 1, 2009: |
|
§ |
|
1,130,262 shares held by Master Account |
|
|
§ |
|
154,566 shares held by Capital Partners (100) |
|
|
§ |
|
1,229,817 shares held by Institutional Partners II |
|
|
§ |
|
3,098,284 shares held by Institutional Partners IIA |
|
o |
|
1,095,658 shares of Common Stock that can be obtained by the following
entities upon exercise of warrants: |
|
§ |
|
836,896 held by Master Account |
|
|
§ |
|
115,961 held by Capital Partners (100) |
|
|
§ |
|
40,576 held by Institutional Partners II |
|
|
§ |
|
102,225 held by Institutional Partners IIA |
|
o |
|
7,000 shares of Common Stock that can be obtained by Dr. Rachesky upon
the exercise of currently vested stock options at a price of $3.76 per share |
|
|
o |
|
7,000 shares of Common Stock that can be obtained by Dr. Rachesky upon
the exercise of currently vested stock options at a price of $3.79 per share |
ITEM 13. CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE
Related Party Transaction Approval Policy
In February 2007, our Board of Directors adopted a written related party transaction approval
policy, which sets forth our Companys polices and procedures for the review, approval or
ratification of any transaction required to be reported in our filings with the Securities and
Exchange Commission. The Companys policy with regard to related party transactions is that all
material transactions non-compensation related are to be reviewed by the Audit Committee for any
possible conflicts of interest. The Compensation Committee will review all material transactions
that are related to compensation. All related party transactions approved by either the Audit
Committee or Compensation Committee shall be disclosed to the Board of Directors at the next
meeting.
Information about Board of Directors
Our business is overseen by the Board of Directors. It is the duty of the Board of Directors
to oversee the Chief Executive Officer and other senior management in the competent and ethical
operation of the Company on a day-to-day basis and to assure that the long-term interests of the
stockholders are being served. To satisfy this duty, our directors take a proactive, focused
approach to their position, and set standards to ensure that the Company is committed to business
success through maintenance of the highest standards of responsibility and ethics. The Board of
Directors is kept advised of our business through regular verbal or written reports, Board of
Directors meetings, and analysis and discussions with the Chief Executive Officer and other
officers of the Company.
Members of the Board of Directors bring to us a wide range of experience, knowledge and
judgment. Our governance organization is designed to be a working structure for principled actions,
effective decision-making and appropriate monitoring of both compliance and performance.
The Board of Directors has affirmatively determined that Dr. Stephen K. Carter, Mr. John D.
Harkey, Jr., Dr. Mark H. Rachesky, Mr. Kenneth I. Moch and Dr. Michael Weiser are independent
directors within the meaning of Rule 4200 of the Marketplace Rules of the Nasdaq Stock Market, Inc.
(Nasdaq). The independent directors meet in separate sessions at the conclusion of board
meetings and at other times as deemed necessary by the independent directors, in the absence of Dr.
Michael M. Goldberg and Mr. Michael V. Novinski, the non-independent directors. Dr. Goldberg
resigned from the Board of Directors effective March 11, 2008. Mr. Pack passed away on December 9,
2008. Mr. Moch was appointed to the Board of Directors to fill the vacancy created by Mr. Packs
death. Dr. Carter resigned from the Board of Directors effective April 30, 2009.
Committees of the Board of Directors
The Board of Directors has established an Audit Committee, a Compensation Committee and a
Governance and Nominating Committee. Each of the committees of the Board of Directors acts pursuant
to a separate written
charter adopted by the Board of Directors. On February 12, 2007, the Board of Directors also
established an executive committee consisting of Drs. Rachesky, Weiser and Carter, Mr. Pack and Mr.
Harkey.
The Audit Committee is currently comprised of Mr. Harkey (chairman), Mr. Moch and Dr. Weiser.
Mr. Pack served as a member of the Audit Committee until his death on December 9, 2008. Mr. Moch
became a member of the Audit Committee on December 23, 2008. All of the members of the Audit
Committee are independent within the meaning of Rule 4200 of the Nasdaq. The Board of Directors
has determined that Mr. Harkey is an Audit Committee financial expert, within the meaning of Item
401(h) of Regulation S-K. The Audit Committees responsibilities and duties are summarized in the
report of the Audit Committee and in the Audit Committee charter which is available on our website
(www.emisphere.com).
The Compensation Committee is currently comprised of Dr. Weiser (chairman), Mr. Moch and Dr.
Rachesky. Mr. Pack served as the chairman of the Compensation Committee until his death on December
9, 2008. Dr. Carter served on the Compensation Committee until February 12, 2009. Mr. Moch became a
member of the Compensation Committee on February 12, 2009. All members of the Compensation
Committee are independent within the meaning of Rule 4200 of the Nasdaq, non-employee directors
within the meaning of the rules of the Securities and Exchange Commission and outside directors
within the meaning set forth under Internal Revenue Code Section 162(m). The Compensation
Committees responsibilities and duties are summarized in the report of the Compensation Committee
and in the Compensation Committee charter also available on our website.
The Governance and Nominating Committee is currently comprised of Dr. Weiser (chairman), Mr.
Moch and Dr. Rachesky. Mr. Pack served on the Governance and Nominating Committee until his death
on December 9, 2008. Dr. Carter served on the Governance and Nominating Committee until February
12, 2009. Mr. Moch became a member of the Governance and Nominating Committee on February 12,
2009. All members of the Governance and Nominating Committee are independent within the meaning of
Rule 4200 of the Nasdaq. The Governance and Nominating Committees responsibilities and duties are
set forth in the Governance and Nominating Committee charter on our website. Among other things,
the Governance and Nominating Committee is responsible for recommending to the board the nominees
for election to our Board of Directors and the identification and recommendation of candidates to
fill vacancies occurring between annual stockholder meetings.
The table below provides membership information for each committee of the Board of Directors during
2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Governance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
and |
Name |
|
Board |
|
Executive |
|
Audit |
|
Compensation |
|
Nominating |
Howard M. Pack (1)(5) |
|
|
X |
|
|
|
X |
|
|
|
X |
|
|
|
X |
* |
|
|
X |
|
Kenneth I. Moch (1)(6) |
|
|
X |
|
|
|
|
|
|
|
X |
|
|
|
|
|
|
|
|
|
Stephen K. Carter, M.D.
(2)(8) |
|
|
X |
|
|
|
X |
|
|
|
|
|
|
|
X |
|
|
|
X |
|
John D. Harkey, Jr. (2) |
|
|
X |
|
|
|
X |
|
|
|
X |
* |
|
|
|
|
|
|
|
|
Michael M. Goldberg, M.D.
(3)(4) |
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Michael V. Novinski (3) |
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mark H. Rachesky, M.D. (3) |
|
|
X |
|
|
|
X |
|
|
|
|
|
|
|
X |
|
|
|
X |
* |
Michael Weiser, M.D. (3)(7) |
|
|
X |
|
|
|
X |
|
|
|
X |
|
|
|
|
|
|
|
|
|
(1) |
|
Class II directors: Term as director is expected to expire in 2010 |
|
(2) |
|
Class I directors: Term as director is expected to expire in 2009 |
|
(3) |
|
Class III directors: Term as director is expected to expire in 2011 |
|
(4) |
|
Dr. Goldberg resigned from the Board of Directors effective March 11, 2008 |
|
(5) |
|
Mr. Pack passed away on December 9, 2008 |
(6) |
|
Mr. Moch was appointed to the Board of Directors on December 23, 2008 to fill the
vacancy created by the death of Mr. Pack. He was appointed to the Audit Committee on
December 23, 2008 and was appointed to the Compensation Committee and Governance and
Nominating Committee on February 12, 2009. |
|
(7) |
|
On February 12, 2009, Dr. Weiser was appointed to the Compensation Committee and
Governance and Nominating Committee and assumed the role of chairman of both committees. |
|
(8) |
|
Dr. Carter resigned from the Board of Directors effective April 30, 2009. |
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
The following table presents fees for professional audit services rendered by
PricewaterhouseCoopers LLP (PwC) for the audit of our annual financial statements for the years
ended December 31, 2008 and December 31, 2007, and fees billed for other services rendered by PwC
during the respective periods.
|
|
|
|
|
|
|
|
|
Types of Fees |
|
2008 |
|
2007 |
Audit Fees (1) |
|
$ |
787,000 |
|
|
$ |
819,000 |
|
Audit-Related Fees |
|
|
|
|
|
|
|
|
Tax Fees |
|
|
|
|
|
|
|
|
All Other Fees (2) |
|
|
|
|
|
|
98,230 |
|
|
|
|
(1) |
|
Audit fees for 2008 and 2007 were for professional services rendered for the audit of
the Companys financial statements for the fiscal year, including attestation services
required under Section 404 of the Sarbanes-Oxley Act of 2002, and reviews of the Companys
quarterly financial statements included in its Form 10-Q filings.
|
|
(2) |
|
All other fees are for services related to our registration statements on Form S-3 and
S-8 and financing transactions during 2007. |
The Audit Committee has determined that the independent registered public accounting firm did
not provide non-audit services in 2008 and that the registered public accounting firms
independence was not impaired. All decisions regarding selection of independent registered public
accounting firms and approval of accounting services and fees are made by our Audit Committee in
accordance with the provisions of the Sarbanes-Oxley Act of 2002 and related SEC rules.
The Audit Committee pre-approves all audit and permissible non-audit services provided by the
independent registered public accounting firm; these services may include audit services, audit
related services, tax services and other services. The committee has adopted a policy for the
pre-approval of services provided by the independent registered public accounting firm, where
pre-approval is generally provided for up to one year and any pre-approval is detailed as to the
particular service or category of services and is subject to a specific budget. For each proposed
service, the independent auditor is required to provide detailed communication at the time of
approval. The committee may delegate pre-approval authority to one or more of its members, who must
report same to the committee members at the next meeting. The Audit Committee, after discussion
with PwC, agreed that any additional audit or tax service fees could be paid by us, subject to the
pre-approval of the Audit Committee chairman.
The Audit Committee intends to select PwC to serve as independent registered public accounting
firm for the fiscal year ending December 31, 2009. PwC has served as Emispheres independent
registered public accounting firm since November 1991.
PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(3) Exhibits
|
|
|
Exhibit |
|
|
|
31.1
|
|
Certification Pursuant to Rule 13a-14(a) and 15d-14(a), as adopted
pursuant to section 302 of the Sarbanes-Oxley Act of 2002* |
|
|
|
31.2
|
|
Certification Pursuant to Rule 13a-14(a) and 15d-14(a), as adopted
pursuant to section 302 of the Sarbanes-Oxley Act of 2002* |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
|
|
|
|
|
Emisphere Technologies, Inc.
|
|
|
By: |
/s/ Michael R. Garone
|
|
|
|
Michael R. Garone |
|
|
|
Chief Financial Officer |
|
|
Date: April 30, 2009
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been
signed below by the following persons on behalf of the registrant and in the capacities and on the
dates indicated.
|
|
|
|
|
Name and Signature |
|
Title |
|
Date |
|
/s/ Michael V. Novinski
Michael V. Novinski |
|
President and Chief Executive Officer
(principal executive officer)
|
|
April 30, 2009 |
|
|
|
|
|
/s/ Michael R. Garone
Michael R. Garone |
|
Chief Financial Officer (principal financial and accounting
officer)
|
|
April 30, 2009 |
EXHIBIT INDEX
|
|
|
Exhibit |
|
|
|
31.1
|
|
Certification Pursuant to Rule 13a-14(a) and 15d-14(a), as adopted
pursuant to section 302 of the Sarbanes-Oxley Act of 2002* |
|
|
|
31.2
|
|
Certification Pursuant to Rule 13a-14(a) and 15d-14(a), as adopted
pursuant to section 302 of the Sarbanes-Oxley Act of 2002* |